Abstract
Biological drugs as specialty medications have been a significant driver of drug expenditures for payers. Biologic disease-modifying antirheumatic drugs (DMARDs) are effective but costly treatments as payer’s perspective. Over the past two decades, Medicaid has been the primary public payer for DMARDs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
